Modern Healthcare Technology Holdings Limited (0919) AI Stock Analysis

• Market Cap: HK$80.50M
• Dividend Yield: N/A
• Average Volume (3M): 71.60K
• Price to Earnings (P/E): 2.6
• Beta (1Y): -0.02
• Revenue Growth: -3.40%
• EPS Growth: 515.63%
• Country: HK
• Employees: 850
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Personal Products & Services
• EPS (TTM): <0.01
• Shares Outstanding: 904,483,950
• 10 Day Avg. Volume: 65,200
• 30 Day Avg. Volume: 71,600
• PEG Ratio: 0.28
• Price to Book (P/B): 0.36
• Price to Sales (P/S): 0.15
• P/FCF Ratio: 0.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: HK$0.08 ▲(0.00% Upside)
• Action: Reiterated Date: 02/11/26
• Date: Action: Reiterated 02/11/26

The score is primarily constrained by weak financial performance (revenue decline, negative profitability, and negative ROE). Technicals are also soft with the stock below key moving averages. Valuation is the main offset, supported by a low P/E.

Positive Factors

Diversified Revenue Streams

The company's multi-pronged revenue model — device sales, software licenses, subscriptions and consulting/maintenance — creates recurring revenue and lowers dependence on single products. Durable diversification supports steadier cash flow and resilience across healthcare customers over months.

Improved Leverage

Measured improvement in debt-to-equity signals stronger balance sheet management and greater financial flexibility. Lower leverage reduces refinancing risk, preserves optionality for R&D or product investment, and improves resilience to sector cyclical pressures over the medium term.

Strong Free Cash Flow Generation

Consistent free cash flow growth and positive cash conversion imply the business can internally fund operations, maintenance and development without heavy external financing. Reliable FCF supports investment in product roadmap and steadies funding for client support contracts over months.

Negative Factors

Declining Revenue Growth

Contraction in top-line growth indicates slower adoption or market share pressure. Sustained revenue decline erodes scale economies and limits funds available for R&D and sales expansion, making it harder to reverse competitive setbacks and restore growth within a 2–6 month horizon.

Negative Profitability and ROE

Negative net margins and ROE show the company is not currently generating returns on shareholder capital. Persisting unprofitability weakens retained earnings, constrains reinvestment capacity, and increases reliance on external funding, which is a lasting structural headwind.

Declining Operating Margins / Efficiency

Falling EBIT/EBITDA margins point to deteriorating cost control or pricing pressure. Operational inefficiencies reduce cash available for strategic investments and weaken competitiveness; addressing these typically requires structural changes that take multiple quarters to implement and show improvement.

Modern Healthcare Technology Holdings Limited Business Overview & Revenue Model

Company Description

Modern Healthcare Technology Holdings Limited, an investment holding company, provides beauty and wellness services in Hong Kong, the People's Republic of China, Singapore, and Australia. The company operates in two segments, Beauty and Wellness Services, and Skincare and Wellness Products. It offers beauty and facial services; aesthetics services, such as skincare treatment, professional consultation, skin care and anti-ageing, and referral services on plastic reconstruction; slimming services, including weight management programs; and spa and massage services comprising resplendent bathroom furnishings and a hydrotherapeutic pool, as well as foot spa, foot treatment, and foot massage services. The company also sells skincare and wellness products under the be, FERRECARE, p.e.n, Y.U.E., Advanced Natural, Malu Wilz, Byotea, Care Plus, Cellnoc, Mu-lan Spa, Cellnoc, Veribe, Castille, Dr Plus, Eclat du teint, and Natural Care brand names. In addition, it provides franchise and trademark services in relation to beautification and gymnastic services; advertising services; maid agency services; and management services, as well as food and beverage services. As of March 31, 2022, the company had 30 service centers in Hong Kong; 3 service centers in Mainland China; and 7 service centers in Singapore, as well as 8 be Beauty Shop outlets. Modern Healthcare Technology Holdings Limited is headquartered in Kowloon Bay, Hong Kong.

How the Company Makes Money

The company generates revenue through multiple streams, primarily by selling its healthcare technology products and services to hospitals, clinics, and other healthcare facilities. This includes software licensing fees, subscription services for ongoing support, and maintenance contracts. Additionally, Modern Healthcare Technology Holdings Limited may engage in partnerships with other technology firms and healthcare organizations, leading to collaborative projects that can enhance its service offerings and increase revenue. The company may also benefit from government contracts or grants aimed at improving healthcare technology infrastructure, further contributing to its financial growth.

Modern Healthcare Technology Holdings Limited Financial Statement Overview

Summary

Income statement weakness (declining revenue growth and negative net margins) and negative ROE weigh on results, partially offset by improved leverage and relatively strong free cash flow generation.

Income Statement

The company has experienced declining revenue growth, with a negative growth rate in the most recent year. Gross profit margins remain healthy, but net profit margins are negative, indicating profitability challenges. EBIT and EBITDA margins have also declined significantly, suggesting operational inefficiencies.

Balance Sheet

The debt-to-equity ratio has improved, indicating better leverage management. However, the return on equity is negative, reflecting ongoing profitability issues. The equity ratio remains stable, suggesting a solid asset base relative to equity.

Cash Flow

The company has shown strong free cash flow growth, indicating improved cash generation capabilities. The operating cash flow to net income ratio is positive, suggesting efficient cash conversion, although the free cash flow to net income ratio indicates room for improvement.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	451.70M	453.27M	454.71M	406.33M	355.59M	431.45M
Gross Profit	95.34M	165.26M	166.96M	394.72M	341.52M	417.67M
EBITDA	121.17M	77.11M	95.68M	70.72M	26.39M	240.65M
Net Income	17.78M	-5.07M	-9.57M	-20.61M	-68.81M	125.72M
Balance Sheet
Total Assets	561.80M	564.46M	611.04M	561.35M	570.96M	669.04M
Cash, Cash Equivalents and Short-Term Investments	301.73M	236.67M	193.66M	177.53M	127.53M	234.34M
Total Debt	62.90M	68.65M	106.57M	40.11M	65.01M	115.07M
Total Liabilities	362.05M	373.26M	416.65M	357.47M	347.75M	376.15M
Stockholders Equity	193.99M	185.85M	189.33M	199.77M	219.58M	289.37M
Cash Flow
Free Cash Flow	153.70M	134.94M	64.08M	125.52M	-29.55M	121.64M
Operating Cash Flow	162.01M	151.09M	78.66M	139.82M	51.31M	123.88M
Investing Cash Flow	-28.23M	-50.50M	8.16M	-13.17M	-79.96M	-2.85M
Financing Cash Flow	-64.34M	-66.24M	-70.60M	-77.31M	-78.46M	-77.89M

Modern Healthcare Technology Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0919, the sentiment is Positive. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.08, and below the 200-day MA of 0.08, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.03 is Neutral, neither overbought nor oversold. The STOCH value of 64.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0919.

Modern Healthcare Technology Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8603	66 Neutral	HK$5.62B	21.31	49.25%	―	56.28%	-9.91%
0922	62 Neutral	HK$288.78M	-14.14	2.99%	9.17%	-7.05%	-43.44%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
1827	57 Neutral	HK$280.00M	44.19	7.67%	―	-20.59%	―
6966	55 Neutral	HK$480.00M	-10.93	-3.06%	1.10%	-38.66%	-161.86%
0919	53 Neutral	HK$80.50M	2.59	10.10%	―	-3.40%	515.63%
8296	48 Neutral	HK$30.24M	-4.31	-3.96%	―	15.60%	62.35%

Modern Healthcare Technology Holdings Limited Corporate Events

Modern Healthcare Tightens 2026 Master Lease Terms and Revises Annual Caps

Modern Healthcare Technology Holdings has signed a supplemental agreement to its 2026 Master Lease Agreement, capping the term of the master lease and all underlying leases at dates not extending beyond 31 March 2028. Following this change, the company has revised its proposed annual caps for the related leasing arrangements to HK$64 million for the year ending 31 March 2027 and HK$2 million for the year ending 31 March 2028, reflecting updated estimates of right-of-use assets under HKFRS 16.

Because the highest applicable percentage ratio for these leasing caps exceeds 25%, the transactions are classified as both continuing connected transactions and a major transaction under Hong Kong listing rules. As a result, the leasing arrangements are subject to enhanced governance requirements, including announcement, circular, independent financial advice, and independent shareholders’ approval, underscoring the material impact of the lease structure on the group’s balance sheet and obligations.

The most recent analyst rating on (HK:0919) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Modern Healthcare Technology Holdings Limited stock, see the HK:0919 Stock Forecast page.

Modern Healthcare Technology Sets 2026 Connected Master Lease, Seeks Independent Shareholder Approval

Modern Healthcare Technology Holdings Limited has entered into a new 2026 Master Lease Agreement with Asia Power to ensure the continuation of leasing existing premises after the expiry of the current 2023 master lease and related individual leases on 31 March 2026. The arrangement is designed to avoid disruption to the group’s operations by securing ongoing access to key properties owned by Asia Power’s subsidiaries in Hong Kong and other markets.

Because Asia Power is wholly owned by a family trust established by Dr. Tsang, a connected person to the company, the new lease arrangements constitute continuing connected transactions under Hong Kong listing rules and trigger reporting, review, announcement, circular, and independent shareholder approval requirements. An Independent Board Committee and an Independent Financial Adviser have been appointed, an extraordinary general meeting will be convened to seek independent shareholders’ approval of the lease arrangements and annual caps, and Dr. Tsang and her associates will abstain from relevant board and shareholder votes.

The most recent analyst rating on (HK:0919) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Modern Healthcare Technology Holdings Limited stock, see the HK:0919 Stock Forecast page.

Modern Healthcare Technology Updates Cayman Islands Office Addresses

Modern Healthcare Technology Holdings Limited has announced a change in the addresses of its Cayman Islands share registrar and transfer office, as well as its registered office, effective from December 9, 2025. This change is part of the company’s operational updates, with the Hong Kong share registrar remaining unchanged, indicating a strategic move to streamline their operations without affecting their Hong Kong-based activities.

The most recent analyst rating on (HK:0919) stock is a Hold with a HK$0.07 price target. To see the full list of analyst forecasts on Modern Healthcare Technology Holdings Limited stock, see the HK:0919 Stock Forecast page.